Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

Dravet syndrome: newer drugs and gene therapies show promise, review finds

☕ Includes a question for the family ↓

Dravet syndromePart of a story we are following · 1 article · See every update
A woman with curly hair lies on a sofa reading an open book in natural daylight.
A woman with curly hair lies on a sofa reading an open book in natural daylight.Photo: Shixart1985 / Wikimedia Commons, CC BY 2.0

If you know a family living with Dravet syndrome, or you just read about it and felt for them, here is the part worth holding onto: researchers say real progress is under way. A new expert review says newer seizure medicines work better, and gene-based treatments are showing promise in important trials.

In an expert review of what is known about Dravet syndrome across the lifespan, the authors report that newer antiseizure medications control seizures better than older ones, often with gains in development, and that pivotal trials of antisense and genetic therapies show promise to transform the disease. Dravet syndrome is a genetic form of epilepsy that starts in babies.

How the study worked

This was not a single experiment. It was a review by experts who pulled together what is known about Dravet syndrome, from the first symptoms through later life, published in Lancet Neurology in December 2026. Because it summarizes the field, the gene-based therapy results it describes are still from trials, not yet everyday care.

What they found

The review starts with how the condition looks. The classic story is a baby of about 6 months, developing typically, who has a long seizure with a fever. Frequent seizures follow.

Over time, most people with Dravet syndrome develop more than one type of seizure. Development can slow, and sometimes skills are lost. A range of other health problems can emerge as well. The review is honest that the outlook has been hard: the condition is linked to a poor prognosis and a high risk of death.

The cause is usually a change in a gene called SCN1A. This gene holds the instructions for a part of the cell that helps brain signals travel, called a sodium channel. The review says changes in this gene are behind Dravet syndrome in 95% of people who have it.

In most families the gene change is new in the child. It was not passed down in the usual way. Still, a parent sometimes carries the change in only some of their cells, which is called mosaicism. That matters for family planning, and the review says it is a reason for genetic counseling.

Now the hopeful part. The review says newer antiseizure medicines show better results at controlling seizures. Those better results are often linked to developmental gains. It also describes pivotal trials of two newer approaches: antisense oligonucleotides, which are small pieces of genetic material designed to act on how a gene works, and gene therapies. The authors say these show promise to transform the disease.

Why does early diagnosis matter?

The review calls early diagnosis essential. When doctors know a child has Dravet syndrome, they can choose the right seizure medicines sooner. Picking well early is tied to better long-term outcomes.

The authors also stress natural history studies. These follow how the condition unfolds over the years without a new treatment. Researchers need that picture to judge whether a new therapy truly changes the course of the condition.

What you can do today

If Dravet syndrome touches your family, write down two questions for the next neurology visit: which of the newer seizure medicines might fit, and whether there are clinical trials to consider. If you have never had genetic counseling, ask about it too, since the review ties it to family planning.

For clinicians and researchers

Design: Narrative review (Lancet Neurol) of Dravet syndrome, a genetic developmental and epileptic encephalopathy caused by pathogenic SCN1A variants in 95% of individuals. No sample size, follow-up or comparator is reported in the abstract.

Main result: No primary endpoint or effect size is reported. The review states that newer antiseizure medications show improved seizure control, often with developmental gains, and that pivotal antisense oligonucleotide and genetic therapy trials show promise.

Main limitation: Narrative review without a stated systematic search or pooled analysis; the abstract gives no quantitative data, so the strength of the evidence for newer therapies cannot be judged from it.

Open question: Whether antisense oligonucleotide and genetic therapies deliver durable seizure control and developmental benefit, for which natural history studies are needed to interpret trial outcomes.

Talk about it at home

Inside your brain, cells pass messages to each other through tiny doors called channels, a bit like people in a row passing notes along. A gene is like a recipe card that tells the cell how to build each door. Scientists studying this form of epilepsy know that when the recipe has a change, the door does not work smoothly, so they are testing ways to help the cell read its recipe better.

Look up together how brain cells send messages to each other, and find pictures or a short video that show it. Then try explaining it back to each other in your own words, as if you were passing secret notes.

Try it at home

Also cited: Lancet Neurology

Keep exploring

Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. Dravet syndrome: newer drugs and gene therapies show promise, review finds. Mongevity. Published November 20, 2026. Accessed November 22, 2026. https://mongevity.science/aging/2026/11/dravet-syndrome-newer-drugs-gene-therapies-promise/
Vancouver
Mongevity Desk. Dravet syndrome: newer drugs and gene therapies show promise, review finds [Internet]. Mongevity; 2026 Nov 20 cited 2026 Nov 22]. Available from: https://mongevity.science/aging/2026/11/dravet-syndrome-newer-drugs-gene-therapies-promise/
APA
Mongevity Desk. (2026, November 20). Dravet syndrome: newer drugs and gene therapies show promise, review finds. Mongevity. https://mongevity.science/aging/2026/11/dravet-syndrome-newer-drugs-gene-therapies-promise/
For your website
<a href="https://mongevity.science/aging/2026/11/dravet-syndrome-newer-drugs-gene-therapies-promise/">Dravet syndrome: newer drugs and gene therapies show promise, review finds</a>

Free to share or quote with credit and a link.

Questions and answers

What is Dravet syndrome?
It is a genetic form of epilepsy that usually starts in babies around 6 months old, often with a long seizure during a fever, followed by frequent seizures.
What causes Dravet syndrome?
Changes in a gene called SCN1A cause it in 95% of people with the condition. The change is usually new in the child.
Why does early diagnosis matter?
It helps doctors pick the right seizure medicines sooner, which the review links to better long-term outcomes.
Are gene therapies for Dravet syndrome available now?
Not as everyday care. The review says pivotal trials of antisense and gene therapies show promise, but they are still being tested.

Sources

  1. Lancet Neurol: Dravet syndrome: clinical features across the lifespan, molecular findings, and therapeutic approaches (PMID 43051189 · DOI 10.1016/s1474-4422(26)00317-0) · 2026-11-21
Report an error